Investors / United States / Aisling Capital
Aisling Capital
Venture capital · New York, NY, United States · North America
Aisling Capital is an investment firm that invests in products, technologies and global businesses that advance health. It invests in both private and public companies using a variety of investment structures, including seed and venture financings, structured debt and royalty deals, and leveraged buyouts.
Invests inHealthcare & Biotech
In its own wordshealthcarelife sciencesbiopharmaceuticalsmedical technologypublic equitiesroyalty financing
Your fit with Aisling Capital
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsAisling Capital lists 69 checked portfolio companies on its own site and is named in 4 funding rounds. Its most frequent entry is Growth, 50% of the companies with a known first round. Its largest themes are Healthcare & Biotech (93%), Fintech (3%) and Industrial & Manufacturing (2%). 80% of its companies are based in United States. It invests most often alongside NEA, Frazier Life Sciences and RA Capital.
Counts come from funding rounds that name Aisling Capital, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Aisling Capital's whole history. Rounds on record name 4 companies; its own site lists 69. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 25% |
| Series B | 25% |
| Growth | 50% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 2 | 0 |
| '26 | 2 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 90th | 69 companies |
| Recent activity | 69th | 2 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 57th | 3% of companies confirmed by a round |
| Sector focus | 96th | 93% in its largest sector |
| Reach | 91th | 8 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| NEA | 7 |
| Frazier Life Sciences | 6 |
| RA Capital | 6 |
| Foresite Capital | 5 |
| Omega Funds | 5 |
| Vivo Capital | 4 |
| ARCH Venture Partners | 3 |
| Altamont Pharmaceutical Holdings | 3 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers5377%
- No longer answers00%
- Points to another company1623%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 93% | 15% |
| Fintech | 3% | 12% |
| Industrial & Manufacturing | 2% | 7% |
| Enterprise Software | 2% | 8% |
| Media & Entertainment | 2% | 4% |
Co-investor network
who it backs companies with, and who they back togetherCompare Aisling Capital head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Aisling Capital| Date | Company | Stage |
|---|---|---|
| 29 Oct 2026 | Series C+ | |
| 28 Jul 2026 | Series B | |
| 3 Sept 2025 | Series A |
Round details for Aisling Capital
Amounts, full round histories and every co-investor in Aisling Capital's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
69 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Aclaris Therapeutics is a biopharmaceutical company that strives to translate scientific discovery into everyday victories in immuno-inflammatory conditions. | Healthcare & Biotech | Portfolio page | ||
| ADMA Biologics, Inc. develops and manufactures products for the treatment of Primary Immunodeficiency Disease and other rare and serious diseases. | Healthcare & Biotech | Portfolio page | ||
| Advion, Inc. develops and provides mass spectrometry and flash purification solutions for various applications. | Healthcare & BiotechIndustrial & Manufacturing | Portfolio page | ||
| Agile Therapeutics develops and commercializes women's healthcare products using its proprietary Skinfusion technology. | Healthcare & Biotech | Portfolio page | ||
| Ajax Health is a global investment firm that partners with industry leaders to build and scale high-quality healthcare businesses | Healthcare & Biotech | Portfolio page | ||
| Portfolio page | ||||
| Ambit Biosciences Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. | Healthcare & Biotech | Portfolio page | ||
| Antios Therapeutics develops innovative therapies to treat and cure hepatitis B virus and other viral diseases. | Healthcare & Biotech | Portfolio page | ||
| Arcus Biosciences creates medicines by advancing validated biology with exceptional chemistry. | Healthcare & Biotech | Portfolio page | ||
FintechHealthcare & Biotech | Portfolio page | |||
Healthcare & Biotech | Portfolio page | |||
| Ascendis Pharma is a biopharmaceutical company that develops new therapies using its TransCon technology platform to improve treatment safety, efficacy, tolerability, and convenience. | Healthcare & Biotech | Portfolio page | ||
Enterprise SoftwareMedia & Entertainment | Portfolio page | |||
| Biohaven is a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including immunology, obesity, neuroscience and oncology. | Healthcare & Biotech | Portfolio page | ||
| The company creates novel covalent small molecules to treat serious and life-threatening diseases. | Healthcare & Biotech | Portfolio page | ||
| BridgeBio develops medicines for genetic conditions | Healthcare & Biotech | Portfolio page | ||
| The company aims to inhibit the active ON state of RAS signaling in cancer, using expert understanding of RAS signaling biology to inform rational drug design. | Healthcare & Biotech | Portfolio page | ||
| CalciMedica is a biopharmaceutical company developing investigational treatments for pulmonary hypertension and acute pancreatitis | Healthcare & Biotech | Portfolio page | ||
| Catalent is a global end-to-end Contract Development and Manufacturing Organization (CDMO), trusted by pharma, biotech and self-care companies to accelerate the development, manufacturing and delivery of products that improve lives. | Healthcare & Biotech | Portfolio page | ||
Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- aislingcapital.com
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 27 Aug 2025
- Companies checked
- 69
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Aisling Capital's profile as data
Pull Aisling Capital's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/aislingcapital.com
# also
GET /v1/firms/aislingcapital.com/portfolio
GET /v1/firms/aislingcapital.com/coinvestors
GET /v1/firms/aislingcapital.com/news